April 30 (Reuters) - Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade. During the first quarter, the Delaware-based company gained worldwide exclusive global rights for Monjuvi, approved by the FDA for the treatment of certain kinds of blood cancer, from MorphoSys AG. In April, the company also announced it had entered into a definitive agreement to acquire Escient Pharmaceuticals, a clinical-stage company involved in the development of treatment of various skin diseases. Sales of Jakafi were down 1% to $571.8 million for the quarter, compared with analysts' expectations of $615.80 million, according to LSEG data. Chief Executive Officer Hervé Hoppenot said, "As anticipated, the revenue growth during the quarter was offset by an inventory drawdown for Jakafi and the typical first-quarter net pricing dynamics." Total revenue for the reported quarter came in at $880.90 million, below estimates of $923.6 million. Revenue generated by the drugmaker in the first quarter from royalties was $126 million, up 9% from a year earlier. Incyte earns product royalty revenues from Novartis AG for the commercialization of Jakafi outside the United States and from Eli Lilly for Olumiant for the treatment of rheumatoid arthritis. Opzelura, which is approved in the U.S. to treat vitiligo and mild-to-moderate atopic dermatitis, recorded revenue of $85.7 million, up 52% from a year earlier. Analysts were expecting a revenue of $66.60 million. Excluding items, the U.S. drugmaker earned 64 cents per share in the quarter, missing estimates of 84 cents per share. (Reporting by Vaibhav Sadhamta; Editing by Vijay Kishore)
Incyte misses quarterly profit on weak sales of lead drug
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...